French immuno-oncology firm OSE Pharma has started a Phase III trial (Atalante 1) of Tedopi, a potential treatment for patients with advanced non-small cell lung cancer (NSCLC).

The trial has been given approval by the company, as well as regulatory agencies and national ethics comittees in France, Italy and Czech Republic.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Patients are currently being enrolled, and the company is awaiting national authorisation from four European countries and the US.

OSE Pharma will start screening eligible HLA-A2 positive patients in the first investigational clinical sites. NSCLC patients will have failed a first line therapy, as provided in the study protocol.

"The initiation of the Phase III trial of Tedopi marks an important milestone of the product’s development."

OSE Pharma CEO Dominique Costantini said: "The initiation of the Phase III trial of Tedopi marks an important milestone of the product’s development, ‘Atalante 1’ being the pivotal study to support its registration in treatment of non-small cell lung cancer.

"We thank all investigational centres involved in the study who, together with our teams, are fully committed to conduct the major step of this development programme."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The trial is designed to evaluate the benefits of Tedopi compared to current standard chemotherapy docetaxel or pemetrexed, which are both approved in second line therapy.Its

Tedopi in second line or third line is administered in HLA-A2 positive patients diagnosed with stage IIIB or IV NSCLC.

Around 500 patients will be included in the Phase III trial, which will be conducted in 70 clinical sites in Europe and in the US.

The trial is expected to be completed in 2018, provided that the recruitment of patients, their observed survival and the safety of the product meet the strict criteria set for this trial.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact